ONCY News and Press, Oncolytics Biotech Inc. From 04/26/23

Oncolytics Biotech® Announces Upcoming Oral Presentation on Randomized BRACELET-1 Trial in HR+/HER2- Metastatic Breast Cancer at the ASCO Annual Meeting Canada NewsWire Oral presentation on BRACELET-1 to take place on June 3, 2023 SAN DIEGO and CALGARY, ...

Oncolytics Biotech® to Participate in a Panel Presentation at Canaccord Genuity's Horizons in Oncology Virtual Conference Canada NewsWire SAN DIEGO and CALGARY, AB , April 12, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) tod...

Oncolytics Biotech® Announces Filing and Mailing of the Management Information Circular in Connection with the Annual General Meeting of Shareholders Canada NewsWire Your vote is important no matter how many votes you hold. Vote today Shareholders who have que...

Oncolytics Biotech® to Participate in a Panel Presentation at Cantor Fitzgerald's The Future of Oncology Virtual Symposium Canada NewsWire SAN DIEGO and CALGARY, AB , March 28, 2023 /CNW/ -- Oncolytics Biotech ® Inc. (NASDAQ: ONCY) (TSX: ONC) to...

2023-03-24 09:00:16 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 24, 2023 – USA News Group –  Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as ...

2023-03-14 09:00:01 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – March 14, 2023 – USA News Group –  Optimism is on the rise as the American Cancer Society is reporting that the five-year survival rate for tho...

Oncolytics Biotech Inc. (ONCY) Q4 2022 Earnings Conference Call March 3, 2023 08:30 ET Company Participants Jon Patton - Director, Investor Relations and Communications Matt Coffey - Chief Executive Officer Thomas Heineman - Chief Medical Officer Andrew de Guttadau...

Oncolytics Biotech press release ( NASDAQ: ONCY ): Q4 GAAP EPS of -$0.14 misses by $0.07 . As of December 31, 2022, the Company reported $32.1 million in cash, cash equivalents and marketable securities. For further details see: Oncolytics Biotech GAAP EPS of -$0.14 ...

Oncolytics Biotech® Reports Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights Canada NewsWire Pancreatic cancer program advancing towards registration path supported by phase 1/2 GOBLET data showing a confirmed complete response and 69% object...

Oncolytics Biotech's® Chinese Development Partner Adlai Nortye Presents Interim Clinical Data Further Demonstrating the Anti-Cancer Activity of Pelareorep-Paclitaxel Combination Therapy in HR+/HER2- Metastatic Breast Cancer at the San Antonio Breast Cancer Symposium PR Newswire ...